Renal cell carcinoma: What’s new in 2018
https://doi.org/10.17650/1726-9776-2018-14-4-48-52
Abstract
This review of renal cell carcinoma describes new diagnostics and treatment standards, new guidelines from international professional organizations, key studies, and some articles of interest for oncological urologists published in 2018.
About the Authors
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: The authors declare no conflict of interest.
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
Competing Interests: The authors declare no conflict of interest.
A. S. Markova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: The authors declare no conflict of interest.
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
Competing Interests: The authors declare no conflict of interest.
References
1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7—30. DOI: 10.3322/caac.21442. PMID: 29313949.
2. Malignant tumors in Russia in 2017 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 250 p. (In Russ.).
3. State of oncological care in Russia in 2017. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena — filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 236 p. (In Russ.).
4. Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on Renal Cell Car-cinoma. European Association of Urology 2018. Pp. 1—70.
5. Marconi L., Dabestani S., Lam T.B. et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69(4): 660—73. DOI: 10.1016/j.eururo.2015.07.072. PMID: 26323946.
6. Patel R.M., Safiullah S., Okhunov Z. et al. Pretreatment diagnosis of the small renal mass: status of renal biopsy in the United States of America. J Endourol 2018;32(9):884—90. DOI: 10.1089/end.2018.0175. PMID: 29978713.
7. Chandrasekar T., Ahmad A.E., Fadaak K. et al. Natural history of complex renal cysts: clinical evidence supporting active surveillance. J Urol 2018;199(3):633—40. DOI: 10.1016/j.juro.2017.09.078. PMID: 28941915.
8. Ristau B.T., Handorf E.A., Cahn D.B. et al. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib—II renal masses: An analysis of the national cancer data base. Cancer 2018;124(19):3839—48. DOI: 10.1002/cncr.31582. PMID: 30207380.
9. Antonelli A., Minervini A., Sandri M. et al. Below safety limits, every unit of glomerular filtration rate counts: assessing the relationship between renal function and cancer-specific mortality in renal cell carcinoma. Eur Urol 2018;74(5):661 —7. DOI: 10.1016/j.eururo.2018.07.029. PMID: 30104082.
10. Janssen M.WW, Linxweiler J., Terwey S. et al. Survival outcomes in patients with large (>7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up. PLoS One 2018;13(5):e0196427. DOI: 10.1371/journal.pone.0196427. PMID: 29723225.
11. Goebell PJ., Muller L., Hubner A. et al. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment — Analyses from the German clinical RCC-Registry. Urol Oncol 2018;36(10):470.e1—9. DOI: 10.1016/j.urolonc.2018.07.007. PMID: 30131294.
12. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(Suppl 5):v58—68. DOI: 10.1093/annonc/mdw328. PMID: 27664262.
13. Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655—9. DOI: 10.1056/NEJMoa003013. PMID: 11759643.
14. Mickisch G.H., Garin A., van Poppel H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966—70. PMID: 11583750.
15. Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8): 2530-40. DOI: 10.1200/JCO.1999.17.8.2530. PMID: 10561319.
16. Bex A., Mulders P., Jewett M. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2018. DOI: 10.1001/jamaoncol.2018.5543. PMID: 30543350.
17. Woldu S.L., Matulay J.T., Clinton T.N. et al. Incidence and outcomes of delayed targeted therapy after cytoreductive nephrectomy for metastatic renal-cell carcinoma: a nationwide cancer registry study. Clin Genitourin Cancer 2018;16(6):e1221—35. DOI: 10.1016/j.clgc.2018.08.001. PMID: 30217763.
18. Mejean A., Ravaud A., Thezenas S. et al. Sunitinib Alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379(5):417—27. DOI: 10.1056/NEJMoa1803675.
19. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)/Kidney Cancer. Version 2.2019. September 17, 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
20. Chen Y.W., Ornstein M.C., Wood L.S. et al. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. Urol Oncol 2018;36(10):470.e19—29. DOI: 10.1016/j.urolonc.2018.06.013. PMID: 30131292.
21. Procopio G., Cognetti F., Miceli R. et al. A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial. J Clin Oncol 2018;36(15):4502.
22. McDermott D.F., Lee J.L., Szczylik C. et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. J Clin Oncol 2018;36(15):4500. DOI: 10.1200/JCO.2018.36.15_suppl.4500.
23. Motzer R.J., Powles Th., Atkins M.B. et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated meta-static renal cell carcinoma (mRCC). J Clin Oncol 2018;36(6):578.
24. Motzer R.J., Penkov K., Haanen J.B.A.G. et al. JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Annals Oncol 2018;29(Suppl 8). Available at: https://doi.org/10.1093/annonc/mdy424.036.
Review
For citations:
Matveev V.B., Markova A.S. Renal cell carcinoma: What’s new in 2018. Cancer Urology. 2018;14(4):48-52. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-4-48-52
Views:
1008
Email this article 